ARDELYX, INC. business relationships
Companies named in ARDELYX, INC.’s 10-K filed 2026-02-19, and public companies whose annual reports name ARDELYX, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in ARDELYX, INC.’s annual report 4
“We had a termination agreement with AstraZeneca (AstraZeneca Termination Agreement), pursuant to which we agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10 % of net sales of tenapanor or other NHE3 products by us or our licensees; and (ii) 20 % of non-royalty revenue received fr...” SEC filing
“(3) Other cost of revenue includes the cost of materials sold to our collaboration partners under product supply agreements, certain costs related to capacity expansion at current and future CMOs and payments due to AstraZeneca.” SEC filing
“License Agreement, dated November 27, 2017, by and between Kyowa Hakko Kirin Co., Ltd. and Ardelyx, Inc.” SEC filing
“| CMO | | contract manufacturing organization | | METiS | | METiS Therapeutics, Inc. |” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.